NCT01929603已完成1 期
A Non-randomised, Open-label, Sequential, Multicentre, Two-part, Phase I Study to Assess the Effect of Rifampicin, a CYP Inducer, on the Pharmacokinetics of Olaparib Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 32
- 试验地点
- 1
- 主要终点
- Pharmacokinetics of olaparib by assessment of maximum plasma olaparib concentration (Cmax)
研究概览
简要总结
This is a 2-part study in patients with advanced solid tumours. Part A will investigate the effect of rifampicin on the PK parameters of olaparib in patients; Part B will allow patients continued access to olaparib after the PK phase and will provide additional safety data.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 99 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •For inclusion in the study, patients should fulfil the following criteria:
- •Provision of written informed consent prior to any study-specific procedures.
- •Patients aged greater than or equal to 18 years.
- •Histologically or, where appropriate, cytologically confirmed malignant solid tumour refractory or resistant to standard therapy or for which no suitable effective standard therapy exists.
- •4 Patients must have normal organ and bone marrow function measured within 28 days prior to administration of investigational product (IP) as defined below: Haemoglobin (Hb) greater than or equal to 10.0 g/dL, with no blood transfusions in the previous 28 days.
- •Absolute neutrophil count (ANC) greater than or equal to 1.5 x 109/L. White blood cells (WBC) greater than 3 x 109/L. Platelet count greater than or equal to 100 x 109/L. Total bilirubin less than or equal to 1.5 x institutional upper limit of normal (ULN) (except in the case of Gilbert's disease).
- •Aspartate aminotransferase (AST), alanine aminotransferase (ALT) less than or equal to 2.5 x institutional ULN unless liver metastases are present, in which case it must be less than or equal to 5x ULN, Serum creatinine less than or equal to 1.5 x institutional ULN.
- •Calculated serum creatinine clearance greater than 50 mL/min (using Cockroft-Gault formula or by 24 hour urine collection).
- •Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to
- •Patients must have a life expectancy of greater than or equal to 16 weeks.
- •Evidence of non-childbearing status for women of childbearing potential, or post menopausal status: negative urine or serum pregnancy test within 28 days of study treatment, confirmed prior to treatment on Day 1 of Part A. Post-menopausal is defined as: Amenorrheic for 1 year or more following cessation of exogenous hormonal treatments.
- •Luteinising hormone and follicle stimulating hormone levels in the post menopausal range for women under 50 years of age.
- •Radiation-induced oophorectomy with last menses greater than 1 year ago. Chemotherapy-induced menopause with greater than 1 year interval since last menses.
- •Surgical sterilisation (bilateral oophorectomy or hysterectomy).
- •Patients are willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations.
- •Patients must be on a stable concomitant medication regimen (with the exception of electrolyte supplements), defined as no changes in medication or in dose within the 2 weeks prior to start of olaparib dosing, except for bisphosphonates, denosumab, and corticosteroids, which should be at a stable dose for at least 4 weeks prior to the start of olaparib dosing.
排除标准
- •Patients should not enter the study if any of the following exclusion criteria are fulfilled.
- •Involvement in the planning and/or conduct of the study (applies to AstraZeneca staff, its agents, and/or staff at the study site).
- •Previous enrolment in the present study.
- •Participation in another clinical study with an IP during the last 14 days (or a longer period depending on the defined characteristics of the agents used).
- •Patients receiving any systemic chemotherapy or radiotherapy (except for palliative reasons) within 2 weeks prior to study treatment (or a longer period depending on the defined characteristics of the agents used). The patient can receive a stable dose of bisphosphonates or denosumab for bone metastases, before and during the study, as long as these were started at least 4 weeks prior to treatment.
- •Patients who have received or are receiving inhibitors or inducers of CYP3A
- •Toxicities (greater than or equal to Common Toxicity Criteria for Adverse Events [CTCAE] Grade 2) caused by previous cancer therapy, excluding alopecia.
- •Any intake of grapefruit, grapefruit juice, Seville oranges, Seville orange marmalade, or other products containing grapefruit or Seville oranges within 7 days of the first administration of the IP until the end of Part A.
- •Patients with brain metastases. A scan to confirm the absence of brain metastases is not required.
- •Major surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of major surgery.
- •Patients considered a poor medical risk due to a serious uncontrolled medical disorder, non malignant systemic disease, uncontrolled seizures, or active uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, extensive bilateral interstitial lung disease on high resolution computer tomography (HRCT) scan, or any psychiatric disorder that prohibits obtaining informed consent.
- •Patients who have diabetes mellitus.
- •Patients who have gastric, gastro-oesophageal, or oesophageal cancer .
- •Patients unable to swallow orally administered medication and patients with gastrointestinal disorders or significant gastrointestinal resection likely to interfere with the absorption of olaparib.
- •Breastfeeding women.
- •Immunocompromised patients, eg, patients who are known to be serologically positive for human immunodeficiency virus (HIV).
- •Patients with known active hepatic disease (eg, hepatitis B or C).
- •Patients with a known hypersensitivity to rifampicin or any of the excipients of the product.
- •Patients with a known hypersensitivity to olaparib or any of the excipients of the product.
- •Resting electrocardiogram (ECG) at screening with measurable QT interval (QT) corrected for heart rate (QTc) greater than 470 msec at 2 or more time points within a 24 hour period or family history of long QT syndrome.
- •Concomitant medication contraindicated for use with rifampicin (including, but not limited to): atazanavir, darunavir, fosamprenavir, ritonavir-boosted saquinavir, saquinavir, or tipranavir.
- •Patients who have jaundice.
- •Patients who weigh less than 50 kg.
- •Clinical judgment by the investigator that the patient should not participate in the study.
研究组 & 干预措施
Olaparib alone, olaparib+rifampicin
Experimental
Sequential treatments of olaparib alone followed by olaparib+rifampicin, with a washout period inbetween.
干预措施: Pharmacokinetic sampling (Procedure)
Olaparib alone, olaparib+rifampicin
Experimental
Sequential treatments of olaparib alone followed by olaparib+rifampicin, with a washout period inbetween.
干预措施: Rifampicin (Drug)
Olaparib alone, olaparib+rifampicin
Experimental
Sequential treatments of olaparib alone followed by olaparib+rifampicin, with a washout period inbetween.
干预措施: Olaparib tablet dosing (Drug)
结局指标
主要结局
Pharmacokinetics of olaparib by assessment of maximum plasma olaparib concentration (Cmax)
时间窗: Blood samples are collected on olaparib dosing days (Day 1 and 14) at pre-dose, 0.25 , 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours post olaparib dose Part A.
Rate and extent of absorption of olaparib following single oral doses of olaparib tablet formulation by assessment of maximum plasma olaparib concentration (Cmax). Olaparib doses are first without, then with rifampicin.
Pharmacokinetics of olaparib by assessment of area under the plasma concentration time curve from zero to infinity (AUC)
时间窗: Blood samples are collected on olaparib dosing days (Day 1 and 14) at pre-dose, 0.25 , 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours post olaparib dose Part A.
Rate and extent of absorption of olaparib following single oral doses of olaparib tablet formulation by assessment of area under the plasma concentration time curve from zero to infinity (AUC). Olaparib doses are first without, then with rifampicin.
Pharmacokinetics of olaparib by assessment of area under the plasma concentration time curve from zero to the last measurable time point, AUC0-t, if AUC is not adequately estimable.
时间窗: Blood samples are collected on olaparib dosing days (Day 1 and 14) at pre-dose, 0.25 , 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours post olaparib dose Part A.
Rate and extent of absorption of olaparib following single oral doses of olaparib tablet formulation by assessment of area under the plasma concentration time curve from zero to the last measurable time point, AUC0-t, if AUC is not adequately estimable. Olaparib doses are first without, then with rifampicin.
次要结局
- Pharmacokinetics of olaparib by assessment of time to reach maximum plasma concentration for olaparib (tmax).(Blood samples are collected on olaparib dosing days (Day 1 and 14) at pre-dose, 0.25 , 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours post olaparib dose Part A.)
- Determine safety and tolerability of olaparib by physical examination(Part A: baseline, Day -1 and within 30 days after last dose. Part B: Day 1.)
- Determine safety and tolerability of olaparib by assessment of clinical chemistry results(Part A: baseline, Days -1, 9, 14, 17. Part B: Days 1,8,15,22,29 then every 4 weeks. Final assessment within 30 days after last dose.)
- Determine safety and tolerability of olaparib by assessment of haematology results(Part A: baseline, Days -1, 9, 14, 17. Part B: Days 1,8,15,22,29 then every 4 weeks. Final assessment within 30 days after last dose.)
- Pharmacokinetics of olaparib by assessment of olaparib area under the plasma concentration time curve from zero to the last measurable time point (AUC0-τ).(Blood samples are collected on olaparib dosing days (Day 1 and 14) at pre-dose, 0.25 , 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours post olaparib dose Part A.)
- Pharmacokinetics of olaparib by assessment of olaparib terminal half-life (t1/2).(Blood samples are collected on olaparib dosing days (Day 1 and 14) at pre-dose, 0.25 , 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours post olaparib dose Part A.)
- Determine safety and tolerability of olaparib by assessment of urinalysis results(Part A: baseline, Days -1, 14, 17. Part B: Day 1 only)
- Pharmacokinetics of olaparib by assessment of olaparib apparent clearance (CL/F).(Blood samples are collected on olaparib dosing days (Day 1 and 14) at pre-dose, 0.25 , 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours post olaparib dose Part A.)
- Pharmacokinetics of olaparib by assessment of olaparib apparent volume of distribution (Vz/F).(Blood samples are collected on olaparib dosing days (Day 1 and 14) at pre-dose, 0.25 , 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours post olaparib dose Part A.)
- Determine safety and tolerability of olaparib by assessment of 12 lead electrocardiograms(Part A: baseline, Days -1, 17 (and within 30 days post last olaparib dose if not in Part B).)
- Determine safety and tolerability of olaparib by assessment of vital signs(Part A: baseline, Days 1,2 and 3. Part B: Days 1,8,15,22,29 then every 4 weeks. Final assessment within 30 days after last dose.)
- Pharmacokinetics of rifampicin by assessment of plasma concentrations of rifampicin during rifampicin dosing period.(Rifampicin is dosed daily from Days 5 to 17 in Part A. Blood samples are collected on Days 5, 9, 14 and 17 at 2 hours post rifampicin dose)
- Demonstration of induction of CYP by assessment of plasma concentrations of 4β-hydroxycholesterol during rifampicin dosing period.(Blood samples are collected on Days 5, 9, 14 and 17 at pre-dose of rifampicin in Part A)
- Assessment of the safety and tolerability of olaparib by collection of adverse event reports(Part A: From baseline, every visit until 30 days after last dose. Part B, from start to 12 months after the last patient has entered Part B)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver ImpairmentSolid TumoursNCT02161770AstraZeneca30
已完成
1 期
Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal or Impaired Kidney FunctionSolid TumoursNCT01894256AstraZeneca56
已完成
1 期
Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver ImpairmentSolid TumoursNCT01894243AstraZeneca31
已完成
1 期
To Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of Olaparib, and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation to Patients With Advanced Solid TumoursSolid TumoursNCT01900028AstraZeneca85
已完成
1 期
To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid CancerSolid TumoursNCT02093351AstraZeneca79